Patrick J. Haley Sells 52,636 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Exelixis Price Performance

NASDAQ:EXEL opened at $37.65 on Friday. The firm has a market capitalization of $10.54 billion, a P/E ratio of 21.27, a PEG ratio of 1.13 and a beta of 0.53. The company’s fifty day moving average price is $34.42 and its 200-day moving average price is $31.54. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $38.43.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Equities analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective for the company. in a research note on Monday. Truist Financial raised their price target on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Piper Sandler boosted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a report on Thursday, January 23rd. Finally, Barclays increased their price objective on Exelixis from $25.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of EXEL. MassMutual Private Wealth & Trust FSB boosted its position in Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 290 shares in the last quarter. Balyasny Asset Management L.P. lifted its stake in shares of Exelixis by 1.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock valued at $573,000 after purchasing an additional 317 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in Exelixis by 4.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after buying an additional 330 shares in the last quarter. Covestor Ltd grew its position in Exelixis by 5.7% during the third quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 341 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its holdings in Exelixis by 0.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after buying an additional 354 shares in the last quarter. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.